Treatment of Polyarticular Juvenile Idiopathic Arthritis
Start methotrexate immediately as first-line therapy—do not delay with NSAID monotherapy alone. 1, 2
Treatment Goal
The therapeutic target is achieving inactive disease, defined as: no active arthritis, no systemic features, normal inflammatory markers, physician global assessment at lowest score, and morning stiffness ≤15 minutes. Maintain this for 6 months on medication for clinical remission. 1
Initial Treatment Algorithm
Step 1: Start DMARD Therapy Immediately
- Methotrexate is the mandatory first-line DMARD over other conventional DMARDs (leflunomide, sulfasalazine) or biologics 1, 2
- Subcutaneous route is preferred over oral for better efficacy 2
- Do NOT use NSAID monotherapy as initial treatment—this is strongly discouraged 2
- An adequate trial of methotrexate is 3 months, though if minimal/no response by 6-8 weeks, escalation may begin 2
Step 2: Add Adjunctive Therapy
NSAIDs:
- Naproxen is the preferred NSAID for adjunctive pain/inflammation control 1
- Allow 8 weeks for NSAID trial, but do not delay methotrexate initiation 1
- Alternative NSAIDs (ibuprofen, meloxicam, celecoxib) acceptable if naproxen unavailable 1
- Avoid aspirin due to toxicity concerns 1
Intra-articular glucocorticoids:
- Use as adjunctive therapy for specific joint involvement 2
- Triamcinolone hexacetonide is strongly preferred over triamcinolone acetonide 2
Bridging oral glucocorticoids:
- Short course (<3 months) conditionally recommended for high/moderate disease activity during DMARD initiation 2
- Do NOT use in low disease activity 2
- Strongly avoid chronic low-dose glucocorticoids regardless of disease activity 2
Escalation Strategy Based on Disease Activity
If Low Disease Activity (cJADAS-10 ≤2.5 with ≥1 active joint):
Options for escalation:
- Intra-articular glucocorticoid injections
- Optimize methotrexate dose
- Add or change biologic 2
If Moderate/High Disease Activity (cJADAS-10 >2.5):
On methotrexate monotherapy:
- Add a biologic to methotrexate rather than switching to another conventional DMARD 2
- Do NOT switch to triple DMARD therapy 2
Biologic options (all used in combination with methotrexate):
- TNF inhibitors: etanercept, adalimumab, golimumab 2
- Abatacept (T-cell costimulation inhibitor) 2
- Tocilizumab (IL-6 inhibitor) 2
- Infliximab requires combination with DMARD (strong recommendation) 2
- JAK inhibitors: emerging evidence supports use 3
- Biosimilars show comparable efficacy/safety to originators 3
Special Considerations for High-Risk Patients:
Patients with high-risk joints (cervical spine, wrist, hip), high disease activity, or risk of disabling damage may warrant initial biologic therapy combined with methotrexate, though DMARD-first remains the general recommendation 2
Monitoring and Treat-to-Target
- Use JADAS-71 or cJADAS-10 to monitor disease activity 1, 4
- High JADAS-71 at 6 months predicts need for biologic therapy 5
- Assess for TMJ involvement regularly as it requires specific management 4, 3
- Screen for uveitis per established protocols 1
Non-Pharmacologic Therapies
Physical and occupational therapy are conditionally recommended for patients with or at risk of functional limitations 2, 4
Critical Pitfalls to Avoid
- Do not delay methotrexate while trialing NSAIDs alone—this increases risk of joint damage 2
- Do not use chronic low-dose oral glucocorticoids—growth suppression and other toxicities outweigh benefits 2
- Do not wait full 3 months if clearly failing methotrexate—escalate at 6-8 weeks if no response 2
- Do not use biologic monotherapy (except possibly for specific TNF inhibitors)—combination with methotrexate is superior 2
- Do not overlook TMJ involvement—requires specific assessment and management 4, 3
Evidence Quality Note
The 2025 PANLAR guideline 1 represents the most recent evidence synthesis, though the 2019 ACR/Arthritis Foundation guidelines [2-2] provide more granular detail on specific interventions. Both emphasize that evidence quality is low-to-very-low for most recommendations (90% in ACR guidelines), reflecting the challenges of pediatric rheumatology research. The Asia-Pacific guidelines 4 provide important regional adaptations emphasizing methotrexate-first approaches and biosimilar use where biologic access is limited.